- Home
- TCRX vs PAVM Comparison
TCRX vs PAVM Comparison
Compare TCRX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | PAVM |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 41.1M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TCRX | PAVM |
|---|---|---|
| Price | $0.24 | $2.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $1.00 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 761.4K | 25.0K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,325,000.00 | $3,000,000.00 |
| Revenue This Year | N/A | $132.39 |
| Revenue Next Year | N/A | $263.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | 20.00 |
| 52 Week Low | $0.22 | $0.21 |
| 52 Week High | $2.57 | $28.44 |
Technical Indicators
Market Signals| Indicator | TCRX | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 30.04 |
| Support Level | N/A | $0.21 |
| Resistance Level | $0.37 | $6.56 |
| Average True Range (ATR) | 0.03 | 0.33 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 12.62 | 12.00 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.